테르부탈린

용도

• For acute exacerbations of feline asthma treated at home
• For feline asthma
• For bradyarrhythmias
• For acute bronchoconstriction (initial crisis)
• For use as a quantitative intradermal terbutaline sweat test (QITST) to identify anhidrosis
• General bronchodilation
• For a trial to treat intrathoracic tracheal collapse, expiratory cough or dyspnea and marked exercise intolerance
• As a bronchodilator in chronic bronchitis
• For bradyarrhythmias
• For treatment of premature labor
• For tracheal collapse

투여 방법

가능한 부작용

• Increased heart rate (tachycardia)
• Tremors
• CNS excitement (nervousness)
• Dizziness
• Sweating (reported in horses after parenteral injection)
• Transient hypokalemia
• Tachycardia
• Muscle tremors
• Restlessness or excitement
• Hypokalemia (with high doses or prolonged use)
• Hypertension or hypotension

주의사항 및 금기

• Known hypersensitivity to terbutaline
• Heart disease (especially congestive heart failure or cardiomyopathy)
• Known hypersensitivity to terbutaline or sympathomimetic amines
• Severe cardiac arrhythmias
• Hypertrophic cardiomyopathy (relative contraindication)
• Use with extreme caution in patients with **diabetes mellitus, hyperthyroidism, hypertension, seizure disorders, or cardiac disease** (especially with concurrent arrhythmias). > **Note:** Terbutaline can cause transient hypokalemia. If an animal is susceptible to developing hypokalemia, additional serum potassium monitoring should be performed early in therapy.

약물 상호작용

• Inhalation Anesthetics (e.g., halothane, isoflurane, methoxyflurane): May predispose the patient to ventricular arrhythmias, particularly with preexisting cardiac disease; use cautiously.
• Beta-Adrenergic Blocking Agents (e.g., propranolol): May antagonize the bronchodilating and cardiovascular actions of terbutaline.
• Digoxin: Concurrent use with digitalis glycosides may increase the risk of cardiac arrhythmias.
• Monoamine Oxidase Inhibitors (MAOIs): May potentiate the vascular effects of terbutaline.
• Other Sympathomimetics: May increase the risk of developing adverse cardiovascular effects.
• Tricyclic Antidepressants: May potentiate the vascular effects of terbutaline.
• Beta-blockers (e.g., propranolol): Antagonize the bronchodilating effects of terbutaline
• Sympathomimetics: Additive cardiovascular toxicity and CNS stimulation
• Inhalant anesthetics (e.g., halothane): Sensitize the myocardium, increasing the risk of severe arrhythmias
• Tricyclic antidepressants (TCAs) / MAOIs: May potentiate vascular effects

자주 묻는 질문